ABSTRACT Discovering driver pathways is becoming a key step to uncover the molecular mechanism underlying cancer and to explore precise treatments for cancer patients. Most of the previous works focus on identifying individual pathways. In practice, multiple pathways often cooperatively trigger cancer. In this study, we propose a new approach called CoDP to discover cooperative driver pathways. CoDP firstly uses integrative nonnegative matrix factorization to identify cancer-related comodules (composed with genes and miRNAs) by fusing four types of data, including the expression profiles of miRNAs and genes, miRNAgene interaction data, and gene-gene interaction data of cancer samples. Next, CoDP builds a hybrid network with nodes corresponding to pathways, to genes and miRNAs in comodules, and it further uses tri-random walk on the subnetworks of the hybrid network to update and replenish associations between genes and pathways, and those between miRNAs and pathways. After that, CoDP introduces a quantitative function to quantify the coverage of pathway sets for each comodule based on replenished associations, and identifies the pathway set with the highest coverage as cooperative driver pathways. Empirical study on ovarian (liver) cancer datasets shows that in the identified comodules, miRNAs cooperatively regulate genes, genes (i.e., TP53) and miRNAs (i.e., mir-10b) are statistical significantly associated with the cancer, and others may have potential associations with the cancer. The identified cooperative pathways are involved with key biological processes and carcinogenesis of ovarian (liver) cancer. CoDP also uncovers more known driver genes (over 300%) and cooperative driver pathways (over 200%) than existing methods. The codes of CoDP are available at http://mlda.swu.edu.cn/codes.php?name=CoDP.
I. INTRODUCTION
The high mortality rate of cancer is worrying, but the pathogenesis of cancer is still not well understood. Cancer is mainly caused by the accelerated accumulation of somatic mutations during the survival of the living body. To improve the diagnosis and treatment of cancer patients, several large-scale cancer genomics project (e.g., the Cancer Genome Atlas (TCGA) [1] , and International Cancer Genome Consortium (ICGC) [2] ) were initiated, and mining these high-throughput data provides valuable opportunities to understand the formation and progression of cancer.
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A key step in cancer research is to identify driver mutations and genes that drive the tumor's transition from a normal to a malignant state [3] , [4] . Most of the early studies focus on detecting individual driver genes based on periodic mutation rates of genes in a large population of cancer patients [5] , [6] . However, this kind of methods generally consider the rate as a constant value for all samples in the entire genome, which is not reasonable, since mutations, location, sequence context and gene-specific features can affect the mutation rate [7] . Meanwhile, although individual tumors exhibit diverse somatic cell transplants and copy number mutations, many of these events tend to affect a limited number of biological pathways. Given that, more attention has been paid to discover driver pathways and modules rather than single genes [2] .
According to the number of identified driver pathways, these methods can be divided into two categories, individual and cooperative ones. Based on whether using the prior knowledge or not, these two types of methods can be further categorized into prior knowledge based and de novo ones.
Prior knowledge based individual driver pathways identification approaches can identify significantly mutated subnetworks in a given network and detect frequently mutated driver genes that are members of these subnetworks [8] . For example, HotNet [9] uses a thermal diffusion process on interactive networks to identify individual driver pathways. Wei et al. [10] proposed a gene length-based network method called DriverFinder to distinguish driver genes from integrated mutation networks. However, prior knowledge may be imperfect or even wrong, and thus reduce the reliability of experimental results. Given this, researchers proposed de novo pathway identification methods that combine high exclusivity with high coverage of mutations [11] to identify driver pathways. Dendrix [12] , a representative de novo approach, discovers mutated driver pathways using somatic mutation data. It maximizes a novel weight function combined with the coverage and exclusivity of the gene sets to discover individual pathways, and transforms the maximization problem into a maximum weight submatrix problem, which is solved by an exact binary linear programming (BLP) model [13] . Zhang et al. [14] proposed two de novo models to discover common driver gene sets among multiple cancer types (ComMDP) and specific driver gene sets of a particular cancer (SpeMDP), respectively. Nevertheless, these de novo methods [12] - [14] use only one type of data, unreliable results may be obtained when the used mutation data is not complete enough or the sample size is too small. Even with identified individual pathways, it is still a great challenge to understand how various cellular, physiological processes are coordinately altered in different pathways during the initiation and progression of cancer.
Likewise genes, individual pathways do not work alone. It is recognized that multiple pathways with mutations are involved with the same cancer, and pathways often function cooperatively in carcinogenesis [15] , [16] . For example, TGF-β (transforming growth factor-β) transactivates EGFR (epidermal growth factor receptor) through canonical Smad3 and ERK/Sp1 signaling pathways, and then causes breast cancer migration and invasion [17] . However, due to the difficulties of mapping genes to pathways and the limited knowledge about pathway interactions, works on co-operative driver pathway discovery are much limited compared to individual driver pathway identification. Gu et al. [18] investigated pathway cooperation in cancer cells in terms of superpathways, which are clusters of co-disrupted pathways. CoMDP [19] builds a mathematical programming model to maximize an extended weight function [12] and to find pairwise cooperative driver pathways. All these studies corroborate that the malignant transformation from a normal cell to a tumor is indeed a cooperative procedure involving synergy between pathways. Therefore, identifying cooperative driver pathways is a crucial step to shed new lights on understanding cellular mechanisms underlying tumorigenesis. However, because of the incomplete knowledge about pathways and protein interaction networks, prior knowledge based cooperative pathway identification methods [18] , [20] may be trapped into sub-optimal solutions. De novo cooperative pathway identification methods [19] can identify pathways that are significantly co-disrupted in the same patient, but they only use mutation data, which is far from complete. Given that, Dao et al. [21] proposed BeCo-WithMEFun to pursue the mutual exclusivity, functional interactions within pathways, and the co-occurrence between pathways. By integrating mutation and protein interaction information, BeCo-WithMEFun can discover more patterns of driver pathways, but it can not get a solution when there is insufficient co-occurrences or functional interactions among genes. Furthermore, these cooperative driver pathway identification methods miss important and relevant data in carcinogenesis, such as gene interaction and miRNA-gene regulation data.
High-throughput biotechnologies enable to characterize biological systems at multiple levels. MicroRNAs (miRNAs), transcribed from genes, can regulate gene expression by the role of signal modulators and important components of cancer-relevant pathways, and thus have direct associations with tumor [22] . Both miRNAs and genes can act as oncogenes and tumor suppressors, and they are important components of pathways. Therefore, we should integrate different types of biological data (genes, miRNAs and pathways) to effectively discover cooperative driver pathways. For this purpose, we propose a novel approach called CoDP to discover cooperative driver pathways in cancer initiation and progression. CoDP first uses Sparse Network-Regularized Multiple Nonnegative Matrix Factorization (SNMNMF) [23] , a variant of NMF [24] , to integrate four types of biological data, including miRNA-gene interaction data, gene and miRNA expression data (from TCGA cancer samples), and the genegene interaction data, and thus to obtain disease related comodules (composed with genes and miRNAs). In this step, the gene-gene and miRNA-gene interaction data are used as prior knowledge to enforce that related genes and miRNAs are placed into the same comodule. In addition, a strategy of sparsity penalty is used to enhance the signal-noise separation and to improve the interpretability of the comodules. Next, since the associations between genes, miRNAs and pathways are incomplete, and the aforementioned methods do not directly find exact driver pathways, CoDP leverages genes and miRNAs in comodules to build a gene-gene interaction (GGI) network, an miRNA-miRNA interaction (MMI) network, and then applies tri-random walk on the GGI, MMI and pathway-pathway interaction (PaPaI) networks using the known interactions and inter associations between them to replenish associations. After that, CoDP calculates the coverage of all pathway sets in the PaPaI network for each comodule using the replenished gene-pathway associations and miRNA-pathway associations. After removing disturbed Step 1: CoDP uses SNMNMF [23] to integrate multiple data and to obtain disease related comodules.
Step 2: CoDP performs tri-random walk based on the GGI, MMI, PaPaI networks and the associations between them to replenish associations between genes(miRNAs) and pathways.
Step 3: CoDP utilizes the replenished gene(miRNA)-pathway associations, and identifies the pathway sets with the highest coverage as cooperative driver pathways.
individual pathways, CoDP identifies the pathway sets having the highest coverage as the cooperative driver pathways.
We apply CoDP on 385 ovarian cancer samples and identify 50 human miRNA-gene regulatory comodules. After statistical and biological enrichment analysis (GO biological process terms and KEGG pathways), these identified comodules show strong associations with ovarian cancer. We evaluate the reliability of replenished associations between genes, miRNAs and pathways obtained by tri-random walk via five fold cross validation, and get an AUC larger than 0.85, which supports the credibility of these replenished associations. We finally evaluate the identified cooperative driver pathways and find 70% of them are related to important biological activities. We also apply CoDP on 415 liver cancer samples, and confirm 7 (out of 8) liver cancer carcinogenesis related pathways and their cooperations with other pathways. In addition, CoDP is also readily available to fuse other data types to uncover cooperative driver pathways that trigger various complex diseases.
II. METHODS
CoDP mainly uses three steps (as illustrated in Figure 1 ) to discover cooperative driver pathways. In the first step, it applies SNMNMF [23] to obtain disease related miRNAgene comodules. Next, it performs tri-random walk on a heterogenous network composed with pathways, genes and miRNAs of comodules to replenish gene(miRNA)-pathway associations. In the third step, it combines the results of previous two steps, and introduces a coverage rank approach to identify cooperative driver pathways. The following subsections elaborate on these steps.
A. STEP 1: IDENTIFYING COMODULES
In this step, CoDP fuses multi-type data to find cooperative miRNA-gene modules, and thus to take advantage of complementary information of these data and to get cooperative functional genes and miRNAs, which cause the initiation of cancer. NMF and its variants [24] - [26] can explore sub-structures of the data and have been widely used to fuse multiple data types. Given the sparsity of gene interaction data and to incorporate prior knowledge for identifying coordinated miRNA-gene modules, we employ SNMNMF [23] to integrate different types of data of cancer samples as follows:
where X 1 ∈ R s×m and X 2 ∈ R s×n are the miRNA and gene expression data matrices of m miRNAs and n genes of s samples, respectively. A ∈ R n×n is the adjacency matrix of a gene interaction network, and B ∈ R m×n is the adjacency matrix of a bipartite miRNA-gene network. Since X 1 and X 2 separately correspond to the same samples from the views of miRNAs and of genes, they share the common basis matrix W. H 1 ∈ R k×m and H 2 ∈ R k×n are the two coefficient matrices of X 1 and X 2 , and k is the low-rank size. tr(H 2 AH T 2 ) and tr(H 1 BH T 2 ) are introduced to force genes with interactions and gene-miRNA within the same pathways to have similar coefficient profiles and to place into the same comodule. In this way, comodules are ensured to be tightly connected in signaling network. |W| 2 F limits the growth of W, |H 1 | 2 1 and |H 2 | 2 1 enforce the sparsity and pursue part-based patterns (comodules). λ 1 , λ 2 , γ 1 and γ 2 are scalar weight parameters of respective terms. Due to page limit, the optimization procedure for Eq. (1) is provided in Section 1 of the Supplementary file.
Eq. (1) explores the collaborative relationships between genes and miRNAs by projecting X 1 and X 2 into a common coordinate system W. The obtained coefficient matrices H 1 and H 2 are then used to identify comodules. Previous NMF based methods [27] , [28] use the maximum coefficients in each column of H (or row W) to discover patterns. They presume that each gene (or sample) belongs to only one pattern. In practice, some genes may be active in several comodules and others maybe not in any comodule. For this reason, we use z-score to identify comodules and compute a z-score for each element of H 1 (or of H 2 ) as follows:
where
, µ i is the average value of miRNA (or gene) i, and σ i is the standard deviation. If the i-th miRNA (or gene) is in a comodule if z ij is larger than a given threshold θ. In this way, miRNAs (or genes) in comodules are more significant than other miRNAs (or genes), and they may play important roles to drive carcinogenesis.
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B. STEP 2: REPLENISHING GENE(MIRNA)-PATHWAY ASSOCIATIONS
To enable accurate cooperative driver pathways identification, we can map the disease related miRNA-gene comodules obtained in
Step 1 to pathways to uncover their cooperations in the signaling network. But the known associations between pathways and genes, and those between pathways and miRNAs are still incomplete. To remedy this incompleteness, we introduce a tri-random walk based approach to replenish associations among miRNAs, genes and pathways, and then to map comodules to pathways. For this, we first build a heterogeneous network composed with miRNA-miRNA interaction (MMI) network, gene-gene interactions (GGI) network, pathway-pathway interactions (PaPaI), and the associations between genes and miRNAs, between genes and pathways, and between miRNAs and pathways. Only genes and miRNAs in the comodules contribute to the carcinogenesis, we exclude the nodes not in the comodules from the heterogeneous network to reduce the scale and to improve the performance. Suppose G ∈ R g×g , P ∈ R p×p and M ∈ R m×m are the adjacency matrices of GGI, PaPaI and MMI networks, respectively. A gp ∈ R g×p , A mp ∈ R m×p and A gm ∈ R g×m store the known gene-pathway associations, miRNApathway associations and gene-miRNA associations. Each entry of these matrices has a value 1 if there is an association between the respective nodes; 0 otherwise. R gp ∈ R g×p and R mp ∈ R m×p denote the predicted gene-pathway and miRNA-pathway associations, respectively.
The basic idea of applying tri-random walk on the heterogeneous network is that the unknown associations between genes (miRNAs) and pathways can be inferred from genes (miRNAs) and their interaction partners, which may be associated with a shared pathway. Therefore, R gp can be updated in three ways. (i) Several random walk steps (l 1 ) are taken in the GGI network to replenish gene-pathway associations from level-l 1 neighbors of genes (Eq. (3)). (ii) Several random walk steps (r 1 ) are taken in the PaPaI network to obtain gene-pathway associations from level-r 1 neighbors of pathways (Eq. (4)), such that pathways can be co-associated with common genes with their direct or up to level-r 1 neighbors. (iii) The gene-pathway associations can be further updated by traveling from the known gene-miRNA associations to updated miRNA-pathway associations (Eq. (5)).
where t is the number of walk steps, R t gp is the updated genepathway associations after the t-th iteration and R t−1 mp is the updated miRNA-pathway associations after the (t −1)-th iteration. α controls the weight of the regulation of known genemiRNA associations, it is also called as the restart probability for random walk. We want to remark that, different from other network based inference solutions [29] - [31] that apply global random walk on the whole heterogeneous network, our CoDP applies tri-random walk on the subnetworks of the heterogeneous network to account for the structural difference of GGI, MMI and PaPaI and the associations between them.
Similarly, we also apply tri-random walk on the heterogeneous network to replenish the miRNA-pathway associations. R mp are also updated in three ways. Some potential miRNA-pathway associations can be updated by taking several random walk steps in MMI (l 2 ) (Eq. (6)) and PaPaI (r 2 ) network (Eq. (7)). New miRNA-pathway associations can also be inferred by transferring from the known miRNA-gene associations to updated gene-pathway associations (Eq. (8)).
To better understand the procedure of the tri-random walk on the heterogeneous network, we list the procedure in Algorithm 1. Once the tri-random walk described in Eqs. (3) (4) (5) (6) (7) (8) iterates for more than τ = max{l 1 , l 2 , r 1 , r 2 } steps, or the iteratively updated R gp and R mp become stable, the tri-random walk process stops. These updated R gp and R mp will be used to identify cooperative driver pathways.
C. STEP 3: IDENTIFYING COOPERATIVE DRIVER PATHWAYS
Genes and miRNAs in comodules cooperatively drive carcinogenesis, so we can assume that pathways containing the genes and miRNAs in comodules also have cooperative functions and interactions for carcinogenesis. As a result, pathways maximally involved with these comodules are more likely to be the cooperative driver pathways. Given that, we introduce a coverage quantitative function to seek cooperative driver pathways based on the replenished gene-pathway associations and miRNA-pathway associations. We assume that for each comodule, a set of pathways with the highest union coverage and common coverage are cooperative driver pathways. Suppose (P i ) is the set of common elements (genes and miRNAs) in a comodule and pathway P i . We define the common coverage c(P i , P j ) = | (P i ) ∩ (P j )| and the union coverage u(P i , P j ) = | (P i ) ∪ (P j )|, we then quantify the coverage function as follows:
where | (C)| is the number of elements in a comodule C. The common coverage is calculated twice to strengthen the associations among pathways. Following the setting in [13] , to avoid the main effect of disturbed individual driver pathways, we calculate the coverage rate for each pathway and remove the pathway whose coverage larger than 0.8. We then use the updated gene-pathway association and miRNA-pathway association matrices R gp ∈ R g×p and R mp ∈ R m×p to update (P i ).
To this end, we calculate the coverage of a q-pathway set VOLUME 7, 2019 
where c m (S q ) is the common coverage in an miRNA module, and u m (S q ) is the union coverage in an miRNA module. r m (S q ) and r g (S q ) are the respective coverage rates of S q in an miRNA module and a gene module. c g (S q ) and u g (S q ) have the same meanings in gene modules. (C m ) and (C g ) are the respective sets of miRNAs and genes in a comodule. Finally, for each comodule, CoDP identifies a q-pathway set with the highest coverage as the cooperative driver pathway set.
III. EXPERIMENTAL RESULTS

A. DATA SOURCES AND PREPROCESSING
To investigate the effectiveness of CoDP, we carry out experiments on publicly available cancer data of ovarian. The miRNA-gene interactions were obtained from [32] , genegene interactions (version 3.4.154) were downloaded from the BioGrid database [33] , and the expression profiles of miRNAs and genes for 385 ovarian cancer samples were collected from TCGA (version 20160128). To make the input data fit the constraints of nonnegativity for Nonnegative Matrix Factorization (NMF), before matrix factorization, we transform the two expression matrices into nonnegative ones based on the technique used by [28] . Particularly, the columns (gene and miRNA expression values) of each matrix are doubled, such that each variable (gene, miRNA) is represented with two columns in the respective matrix. If the original value is positive, then it is stored in the first column; otherwise, its absolute value is stored in the second column. The rest of the doubled matrix are filled with zeros. Since interacting miRNAs are likely to have similar functions, we also collected a functional similarity network of miRNAs from Cui's lab (http://www.cuilab.cn/misim.zip) and call this network as MMI network [34] . The PaPaI network data and gene-pathway association data were downloaded from PID databse [35] . Multiple miRNAs' expressions change during tumorigenesis and development, and cascade to downstream target gene expression in the signaling pathway, and thus affect tumor progression. We assume that an miRNA and a pathway are more likely to be associated if they are associated with the same gene, so we construct the miRNA-pathway association network based on known gene-pathway and genemiRNA associations. This process produces a GGI network with 12,456 genes and 31,949 interactions, an MMI network with 559 miRNAs, a PaPaI network with 212 pathways, a gene-miRNA network with 243,331 associations, a genepathway network with 1,411 interactions and an miRNApathway network with 6,582 associations.
B. STATISTICAL ENRICHMENT ANALYSIS OF IDENTIFIED COMODULES
To obtain disease related comodules, we fix the low rank size k in the first step to 50, which is close to the number of miRNA clusters in our data. We set the weight parameters λ 1 , λ 2 , γ 1 and γ 2 to 0.0001, 0.01, 20, 10. The influences of these parameters are studied in Section 2 of the supplementary file. θ is set as 7, since the peak of enrichment rate of gene modules with respect to GO biological process is achieved when θ = 7 ( Figure S3 of the supplementary file) . Among the 50 identified comodules, two comodules contain only genes. On average, each comodule includes 2.9 miRNAs and 61.7 genes. For convenience and discussion, we number these modules from 1 to 50, which are provided at the end of Supplementary file.
We expect that within a comodule, miRNAs and genes are highly correlated, as such we calculate the statistical 77742 VOLUME 7, 2019 significance of comodules. An miRNA-gene comodule is a pair of sub-matrices (sX 1 and sX 2 ) extracted from X 1 and X 2 . Firstly, the correlation between two matrices with the same row dimension is the sum of the Pearson's correlation coefficients between any two columns, one from each matrix. The statistical significance (P-value) of the correlation between sX 1 and sX 2 is derived by comparing it with the distribution of correlations between 1000 random pairs of sub-matrices (X 1 and X 2 ) using permutation test. Based on a distribution of correlations derived from randomized miRNA-gene comodules, the correlations between miRNAs and genes are statistically significant in 70% of the comodules (permutation test with P-value < 0.05), indicating CoDP can effectively identify disease related comodules with statistical significance.
C. BIOLOGICAL ENRICHMENT ANALYSIS OF IDENTIFIED COMODULES
Comodules are enriched in miRNA clusters. It is evident that miRNAs often work together in a combinatorial regulation [36] . The discovered miRNA-gene comodules may uncover these cooperative roles. Seven of the identified comodules are significantly enriched in at least one miRNA cluster, defined as a set of miRNAs that are located within 50kb of each other in the genome. Table 1 shows miRNA modules that are enriched in miRNA clusters. Based on literature search, as shown in Table 2 , we find that spatially clustered miRNAs have similar functions or play cooperative roles. In comodule 9, its member mir-449a and 449b were reported to have a tumor suppressing function by regulating Rb/E2F1 activity [37] . In addition, mir-34b* and 34c-5p were reported to be targeted by p53 and cooperatively control cell proliferation in ovarian cancer [38] . These evidences show that our comodules can group miRNAs with cooperative roles. Comodules are also enriched in known functional sets. To evaluate the biological revelance of these 50 comodules, we calculate their enrichment in GO biological process terms and KEGG pathways analysis using DAVID6.8 [39] . 30/50 (60%) of the gene modules have at least one over-represented biological process term with an FDRcorrected P-value < 0.05. These 50 modules are enriched in 62 KEGG pathways. The most frequently enriched biological processes are carcinogenesis related activities, such as immune response, DNA binding, cell differentiation and gene expression (see Table S1 of the Supplementary file). Compared to a same test on 1000 random modules, only 2.8% are enriched in any GO biological process term. These evidences demonstrate that genes in a comodule tend to participate in the same important processes or pathways, and also show that these comodules can effectively group function cooperative genes.
The miRNA-gene comodules are strongly implicated in ovarian cancer. We further use a cancer miRNA benchmark dataset of 147 miRNAs from a review article [40] for experiment, and 41 of them are related with ovarian cancer. The identified comodules include 145 miRNAs and 21 of them are in these related miRNAs (Fisher exact test P-value < 0.05), as Table 3 shows. In addition, 9 gene modules significantly include all the known ovarian cancer genes. For example, 11 confirmed ovarian cancer genes are included in the 127 genes of comodule 10. This comodule is also associated with several cancer-related pathways, including cell communication, TGF β signaling pathway and PPAR signaling pathway [41] , [42] . In addition, each comodule includes at least one gene-miRNA interaction. In summary, these comodules show their important roles in ovarian cancer. In other words, CoDP can find cooperative driver gene and miRNA sets of ovarian cancer.
Gene modules are tightly connected in the signaling network. We visualize the gene modules in the signaling network obtained from the Pathway Commons [53] , SPIKE [54] and SignaLink [55] . We find that each gene module contains more than one within interactions. As an example, we visualize the comodule 43 in Fig. 2 . As shown in Fig. 2 , genes within modules are tightly connected, which confirms that genes in comodules are likely to be involved with cooperative pathways which interact with each other. The well-known driver genes of ovarian BRCA2 [56] is included and acts as a downstream of many other genes in this module. This observation indicates that comodule 43 contains pathways involved with ovarian. In addition, the hub nodes of the signaling network include BRCA2, CCNB1 and FOXM1. Chk1-induced CCNB1 over-expression promotes cell proliferation and tumor growth in human colorectal cancer [57] ; and the FOXM1 transcription factor gene is over-expressed in cancer and is also a target of regulation by the tumor suppressor genes [58] . The whole network is driver genes connected by these important genes. Therefore, we can say that pathways covered by comodule 43 play important and cooperative roles in the ovarian cancer. Compared with connections between comodules, there are more associations (over 10%) within gene modules, which indicates that these gene modules are tightly connected in pathways themselves, and interact with miRNA modules by the regulations between genes and miRNAs.
D. ASSOCIATIONS REPLENISHED BY TRI-RANDOM WALK ARE CREDIBLE
To evaluate whether the replenished associations are credible or not, we divide known miRNA-pathway associations into five parts, four of which are regarded as training set and the rest one as testing set. The top ranked p miRNApathway associations are regarded as predicted ones. The receive operating characteristic (ROC) curve can be drawn by varying the true positive rate (TPR, sensitivity) against the false positive rate (FPR, 1-specificity) with different input values of p. The area under the ROC Curve (AUC) can be computed to quantify the overall performance. The larger the AUC value, the better the performance is. Table S2 and  Table S3 of the Supplementary file show that with different settings of walking steps and α, the tri-random walk can usually achieve high AUC score (average over than 0.8). Because of the structural difference of GGI, PaPaI and MMI networks, and the extremely sparse GGI, the AUC value drops to 0.64 when l 1 is set extremely large to 100. Generally, α, r 1 , l 2 and r 2 have little influence on the performance of tri-random walk. So we simply set α, l 1 , r 1 , l 2 and r 2 as 0.1, 1, 1, 1 and 1, respectively. In practice, we also applied tri-random walk to predict the associations between genes and pathways, and obtained similar observations. In summary, the tri-random walk adopted by CoDP in Step 2 can effectively predict associations between miRNAs(genes) and pathways. These replenished associations are credible for follow-up exact cooperative driver pathways identification.
E. ANALYSIS OF IDENTIFIED COOPERATIVE DRIVER PATHWAYS
The cooperative driver pathways identified by CoDP show strong relation with ovarian cancer and important biological activities. The whole results are shown in Table S4 and  Table S5 of the Supplementary file, some representative cases are reported in Table 5 and Table 6 . 6/7 (86%) known pan-cancer related pathways are correctly identified by CoDP, including Class I PI3K signaling events mediated by Akt, p53 pathway, Signaling events mediated by VEGFR1 and VEGFR2, TGF-β receptor signaling, Canonical Wnt signaling pathway and Notch signaling pathway [59] . In addition, each of the 35/50 (70%) cooperative pathway pairs has at least one pathway related to biological processes in carcinogenesis, such as cell cycle, cell death and so on. Besides, as shown in Table 4 , 8/10 (80%) ovarian cancer related pathways are included in these pathway sets. That is because CODP accurately predictes gene(miRNA)-pathway associations in Step 2 and adopts the new coverage quantification in Step 3, which contribute to more than 50% of genes(miRNAs) of each disease related comodule contained in the identified cooperative driver pathways. We can conclude that identified cooperative driver pathways show strong relationship with ovarian cancer. These prominent results can be attributed to that CoDP takes into account both the biological significance and cooperation of pathways, and the replenished gene (miRNA)-pathway associations.
From Table 5 , we can find that identified driver pathway pairs play important roles in the life activities related to the initiation of cancer. For example, in pathway pair 21, ATM pathway provides the crucial link between DNA damage, cell cycle progression and cell death by first sensing double stranded DNA breaks, and subsequently phosphorylating and activating other downstream proteins functioning in DNA damage repair, cell cycle arrest and apoptotic pathways [60] . In pathway pair 34, expression of the epidermal growth factor (EGF) receptor on malignant cells of epithelial origin results in dysregulation of major signaling pathways that control cell proliferation, senescence, differentiation, and apoptosis [61] . We check the cooperation between the pathways identified by Li et al. [62] and find that there do exist cooperations among those pathways. Pathway pair 21, 28, and 50, are reported to have interactions with each other. As well as that, Cell Surface in pathway pair 50 is reported to interact with Canonical Wnt signaling pathway in pathway pair 15 and 46. In addition, Cell Surface interacts with many other important pathways such as Cellular Defense Response and T Cytotoxic Cell Surface Molecules and so on [62] , [63] . We can expect that Cell Surface plays an essential role not only in Normal life activities, but also in carcinogenesis. The identified cooperations between these important pathways with other pathways can greatly help us to understand the interactions between pathways in carcinogenesis. As for the pathway pairs that have not been reported to be cooperative, they can inspire us to further study their potential cooperations in carcinogenesis.
When we set the number of pathways in a cooperative driver pathway set as 3, as Table 6 and Table S5 of the Supplementary file shows, 58% of them are overlapped with the identified cooperative pathway pairs, and the rest firstly appear. For example, in pathway set 43, ATM pathway also appears in driver pathway pairs, it may have many interactions and execute its own function through collaboration with other pathways. Moreover, in pathway set 2, Class I PI3K signaling events mediated by Akt firstly appears, and it is a very important pathway in ovarian cancer. The over-expression of PI3K, a upstream activator of AKT, was observed in ovarian cancer, and elevated PI3K signaling is considered as a hallmark of cancer [64] . Within these pathway sets, pathway set 2, 10, and 37 include at least 2 pathway interactions. Among these pathway sets, p53 pathway in pathway set 2 associates with Cascade In Apoptosis in pathway set 18 and Negative Regulation Of Progression through Cell Cycle in pathway set 37. p53 pathway is reported to interact with most pathways involved with cell activities like cell growth and cell apoptosis in normal life [65] . This phenomenon is still held in the carcinogenesis. Therefore, we can infer that p53 plays core roles in disease occurrences and development by its cooperations with cell activity related pathways. These discovered cooperative driver pathway sets can provide more potential cooperations among pathways without losing identified cooperations between pathway pairs. These discovered driver patterns can provide new insights to deepen our understanding of the ovarian carcinoma pathogenesis, and further biological explorative experiments can be conducted to verify their biological relevances.
We also investigated CoDP on the liver cancer data and also obtained statistically and biologically significant cooperative driver pathways related to liver cancer. By applying CoDP on 415 liver cancer samples, we get 50 cooperative driver pathway pairs and sets (Table S6 and Table S7 of the Supplementary file). 4/7 (57%) of known pan-cancer related pathways are identified, including Class I PI3K signaling events mediated by Akt, Signaling events mediated by VEGFR1 and VEGFR2, Canonical Wnt signaling pathway and Notch signaling pathway. Furthermore, 7/8 (87.5%) of liver cancer related pathways are contained in the 50 identified cooperative driver pathway sets (detailed results are reported in Section 6 of the Supplementary file). In addition, by literature search, 40/50 (80%) of the identified driver pathway sets cooperatively have tight relationship with important biological activities, such as cell proliferation, apoptosis and differentiation and so on. Therefore, we can conclude that CoDP can effectively identify driver pathways of liver cancer and their potential cooperations with other pathways.
F. COMPARISON WITH OTHER METHODS
We take individual driver pathway identification methods: GA [13] , Dendrix [12] , BLP [13] ; and cooperative driver pathway methods: CoMDP [19] as comparing methods to comparatively study the performance of CoDP on ovarian cancer data.
We first compare them on the number of driver genes of ovarian cancer and statistical significance based on the driver genes identified by Vogelstein et al. [56] . As Table 7 shows, CoDP outperforms the five comparing methods both on the number and on the statistical significance. In addition, CoDP identifies the driver genes of ovarian with 100% accuracy, indicating CoDP can identify driver genes more accurately than comparing methods. This perfect accuracy is because that CoDP integrates the knowledge of genes and miRNAs to better reflect how they cooperatively drive diseases, and the tri-random walk to reserve the driver genes in comodules.
We further compare CoDP against the five competing methods at the pathway level. These comparing methods can only obtain one/several set(s) of driver genes. To enable comparison, for each driver gene set identified by these methods, we adopt the same coverage quantitative function (see Eqs. (9-12)) in Step 3 and take pathways with the highest coverage in the candidate pathways as the driver pathways based on the known gene-pathway associations. The common pathway coverage rates between CoDP and each of these five comparing methods are all 100%. As Table 8 shows, these pathways play important roles in the biological activities and can be driver pathways once perturbed. In addition, cooperations exist among those pathways, for example, Notch signalling can either suppress or increase p53 activity in a context-dependent manner that is closely connected to tumour promotion or suppression [65] . Therefore, CoDP can discover all the individual driver pathways discovered by these methods, and their cooperations with other pathways. That is because CoDP can accurately map the disease related comodules to pathways by the introduced coverage quantitative function (Step 3), and reserve the functional and cooperative characteristics of comodules by tri-random walk. Based on these results, we can state that CoDP can better uncover how pathways (especially multiple pathways) drive the complex diseases than existing solutions.
CoDP can discover much more cooperative driver pathways than CoMDP and BeCo-WithMEFun. That is because CoDP fuses multi-type biological data to discover more potential cooperative relationships between genes and miRNAs, and it alleviates the problem of incomplete gene (miRNA)-pathway associations by replenishing gene (miRNA)-pathway associations via tri-random walk. CoMDP in fact mainly discovers co-occurring pathways with TP53 gene set. While BeCo-WithMEFun has to simultaneously satisfy three types of constraints (mutual exclusivity, co-occurrence and functional interaction), which are too stringent to obtain diverse cooperative driver pathways. In contrast, CoDP can discover more potential cooperative driver pathways containing diverse gene sets. In addition, CoDP can not only discover pathways sets that contain 2 pathways like CoMDP does, but also those include ≥ 3 pathways.
In order to analyse how each step contribute to cooperative driver pathway discovery, we also compare CoDP with CoDP without Step 2 (tri-random walk) to investigate whether tri-random walk can improve the effectiveness of cooperative pathways discovery (results are reported in Table S8 and S9 of the Supplementary file). CoDP without Step 2 only uses known gene(miRNA)-pathway associations to find corresponding pathway sets for comodules. CoDP without Step 2 can identify all pathways discovered by the five comparing methods except p53, which indicates that comodules contain important driver gene set and CoDP can correctly map genes and miRNAs to pathways. But it can only find 3 known pan-cancer related pathways, loses 43% compared with CoDP. In contrast, CoDP can find all the carcinogenesis related pathways and provide more diverse pathway combinations. In addition, CoDP without Step 2 only identifies 6 ovarian cancer related pathways, whereas CoDP identifies 8 (out of 10 candidate pathways). These comparisons corroborate that SNMNMF in step 1 can group driver gene set, tri-random walk in Step 2 can provide credible associations and reserve comodule structure and coverage rank in step 3 can map comodules to pathways.
In summary, the integrative matrix factorization (SNM-NMF) in Step 1 can discover more significant cooperative pathways than existing methods, and the tri-random walk in Step 2 can replenish credible associations between miRNAs(genes) and pathways. As a result, CoDP is more effective than these comparing methods in identifying cooperative driver pathways.
IV. CONCLUSIONS
In this paper, we propose a data integrative approach (CoDP) to discover cooperative driver pathways. CoDP firstly uses an integrative nonnegative matrix factorization to fuse four types of data, and thus to obtain disease related comodules, in which genes and miRNAs cooperatively contribute to the formulation of cancer. Next, it utilizes tri-random walk on a heterogeneous network composed with nodes of genes, miRNAs and pathways, to replenish associations between genes (miRNAs) and pathways, After that, it identifies cooperative driver pathways based on the coverage of pathway sets and replenished associations. Experimental results on public ovarian and liver cancer datasets show that CoDP can discover more potential biological cooperations among pathways than individual driver pathway identification methods, and more cooperative driver pathways than the existing related solution. The empirical study also reveals that tri-random walk can replenish credible associations and shed light on gene (miRNA)-pathway association prediction, which is extremely important for pathway research. The codes and datasets are available at http://mlda.swu.edu.cn/codes.php?name=CoDP. 
